 Aimmune Therapeutics NASDAQ:AIMT was upgraded by equities researchers at BidaskClub from a strong sell rating to a sell rating in a report issued on Tuesday, BidAskClub reports. AIMT has been the subject of a number of other research reports. Wedbush reissued a buy rating and set a 66.00 target price on shares of Aimmune Therapeutics ... 